2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

SESSION

907. Outcomes Research: Plasma Cell Disorders: Poster I

Program: Poster Abstract Session
Saturday, December 12, 2026
05:30 p.m. - 07:30 p.m.
MCCNO - Hall F
Access, Representation, Population Health, Technology and Procedures, Imaging, Treatment Considerations, Combination Therapy, Therapy Sequence, Biological Therapies, Transplantation, Bispecific Antibody Therapy, Chimeric Antigen Receptor, (CAR)-T Cell Therapies, Immunotherapy, Monoclonal Antibody Therapy, Adverse Events, Artificial Intelligence (AI), Clinical Practice (Health Services and Quality), Clinical Guidelines, Health Economics, Patient Safety, Practice Models, Quality of Care, Systems-Based Hematology, Diseases, Lymphoid Malignancies, Lymphomas, Plasma Cell Disorders, Myeloid Malignancies, Measurable Residual Disease, Research, Clinical Research, Epidemiology, Health Outcomes Research, Health Disparities Research, Patient-Reported Outcomes, Real-World Evidence, Registries, Study Population, Human, Adult, Elderly
PAPER

2781 Racial disparities in time from initial laboratory abnormality to multiple myeloma-directed evaluation: An all of us analysis

Phoenix Hollenbeck
1 Washington University School of Medicine in St. Louis, Saint Louis, Missouri, United States

Background: Multiple myeloma (MM) disproportionately affects Black patients, whose incidence and mortality are approximately twice those of White patients in the United States. Prior work has shown racial disparities in the completeness of diagnostic evaluation and time from diagnosis to treatment, but whether disparities occur earlier in the diagnostic pathway remains poorly characterized. We examined racial differences in time from the earliest qualifying anemia, creatinine elevation, or hypercalcemia to monoclonal protein evaluation. Secondary outcomes were time from the abnormal lab value to bone marrow (BM) biopsy and from protein evaluation to BM biopsy.

Methods: We conducted a retrospective cohort study using EHR data from the All of Us Research Program (Controlled Tier v9), a national cohort of more than 747,000 enrolled participants designed to include historically underrepresented groups. We restricted patients to those with a BM biopsy linked to at least 1 MM diagnosis code within 90 days and used the earliest eligible biopsy. We identified the first anemia, creatinine elevation, hypercalcemia, or multiple simultaneous lab abnormalities occurring 1-730 days before the BM biopsy. Lab abnormalities were defined using the measuring laboratories' upper and lower bounds when available, and standard thresholds when the required bound was missing. Patients with an MM or precursor diagnosis before the abnormal value were excluded.

The final cohort included all patients with a qualifying lab abnormality, a subsequent monoclonal protein evaluation, and an MM-linked BM biopsy. Monoclonal protein evaluation included serum or urine protein electrophoresis and fractions, immunofixation, serum free light chains, and monoclonal protein measurements. The primary outcome was days from the first abnormal lab value to protein evaluation. Secondary outcomes were days from abnormal lab value to BM biopsy and days from protein evaluation to BM biopsy. All patients were used for overall summaries, but quantile (median) regression was used to compare non-Hispanic Black and non-Hispanic White patients only. Adjusted models included age, sex, abnormal lab type, and year of abnormal lab.

Results: Among 2,347 patients with at least 1 MM diagnosis code, 414 had a qualifying lab abnormality before an MM-linked BM biopsy. Of these, 315 had an intervening monoclonal protein evaluation and formed the cohort. The cohort included 183 non-Hispanic White and 74 non-Hispanic Black patients. The proportion of patients meeting these criteria was similar between White and Black patients (absolute difference, 1.2 percentage points).

For the primary outcome, the overall median lab-to-protein-evaluation interval was 67 days. Median intervals were 52 days among White patients and 135 days among Black patients. Compared with White patients, Black patients had a longer interval in both unadjusted analysis (median difference, 89.8 days; 95% CI, 22.5-157.0; P=.009) and adjusted analysis (90.1 days; 95% CI, 11.3-168.8; P=.025).

For the secondary lab-to-biopsy outcome, the overall median interval was 246 days. Median intervals were 207 days among White patients and 358.5 days among Black patients. The Black-White median difference was 155.9 days in unadjusted analysis (95% CI, 24.6-287.2; P=.020) and 111.2 days after adjustment (95% CI, 8.6-213.7; P=.034).

For the secondary protein-evaluation-to-biopsy outcome, the overall median interval was 28 days. Median intervals were 20 days among White patients and 42 days among Black patients. The Black-White median difference was 23.0 days in unadjusted analysis (95% CI, 4.9-41.1; P=.013) and 18.3 days after adjustment (95% CI, -2.0 to 38.5; P=.077).

Conclusion: Among patients with a complete documented pathway, Black patients experienced significantly longer intervals from the initial lab abnormality to both monoclonal protein evaluation and BM biopsy than White patients. Both of these differences remained statistically significant after adjustment. However, the adjusted difference from protein evaluation to BM biopsy was smaller and not statistically significant, suggesting that the disparity is concentrated before monoclonal protein evaluation. Further studies should validate these findings and identify barriers to timely evaluation.

 

Phoenix Hollenbeck: No relevant conflicts of interest to declare.